Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream genes. At the cellular level, p53 induces apoptosis, cell cycle arrest and senescence. A rare mutant form of p53 with the amino acid substitution R175P, found in human tumors, is completely defective in initiating apoptosis but still induces cell cycle arrest. To decipher the functional importance of these pathways in spontaneous tumorigenesis, we used homologous recombination to generate mice with mutant p53-R172P (the mouse equivalent of R175P in humans). Mice inheriting two copies of this mutation (Trp53(515C/515C)) escape the early onset of thymic lymphomas that characterize Trp53-null mice. At 7 months of age, 90% of Trp53-null mice had died, but 85% of Trp53(515C/515C) mice were alive and tumor-free, indicating that p53-dependent apoptosis was not required for suppression of early onset of spontaneous tumors. The lymphomas and sarcomas that eventually developed in Trp53(515C/515C) mice retained a diploid chromosome number, in sharp contrast to aneuploidy observed in tumors and cells from Trp53-null mice. The ability of mutant p53-R172P to induce a partial cell cycle arrest and retain chromosome stability are crucial for suppression of early onset tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cells harboring this mutation (p53P/P) are incapable of activating p53-dependent apoptosis59, but the p53-dependent cellular senescence pathway is intact as induction of telomere dysfunction through overexpression of TRF2-DN in these cells led to dramatic reduction of cellular proliferation and the appearance of senescent cells that stain positive for SA-β-Gal58.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [59]
Experimental — accuracy not yet measuredIn the citing paper
“Mice homozygous for the p.R172P mutation (equivalent to the human p.R175P alteration) exhibit defects in TP53‐dependent apoptosis but retain a partial cell cycle checkpoint function [44].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 1×
“p53-R172P weakly induced Cdkn1a (encoding p21), a crucial target of p53 in cell cycle contro”
Backgroundp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream gene”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Trp53 -null mice succumb to early tumorigenesis, predominantly thymic lymphoma”
Backgroundp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · cited 1×
“To confirm this finding, we measured apoptosis in freshly isolated thymocytes after γ-radiatio”
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein integrates multiple upstream signals and functions as a tumor suppressor by activating distinct downstream gene”
BackgroundThymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · cited 1×
“Trp53 -null mice succumb to early tumorigenesis, predominantly thymic lymphoma”
BackgroundGenetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986 · cited 1×
“Genomic instability promotes tumorigenesis in multiple setting”
Cited by
Items 101–200 of 324
Cellular Senescence in the Development and Treatment of Cancer
Saretzki, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941874 · Cited by 87
“However, these tumours displayed an extraordinary heterogeneity in treatment responses, ranging from cure to progression under therapy depending on their genotype [53].”
BackgroundInfluentialRoy, S., Tomaszowski, K.-H., Luzwick, J. W., Park, S., Li, J., Murphy, M. E., & Schlacher, K. (2018) · eLife · doi:10.7554/elife.31723 · Cited by 99
“MEF harboring p53 mutations R172P, R172H were previously described (Liu et al., 2004), and MEF harboring p53 mutations S47 and WT p53 and p53 null MEF were previously described (Jennis et al.”
MethodInfluentialDeep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations
Funk, J. S., Klimovich, M., Drangenstein, D., Pielhoop, O., Hunold, P., Borowek, A., Noeparast, M., Pavlakis, E., Neumann, M., Balourdas, D.-I., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02039-4 · Cited by 103
“Several lower-right variants, such as R175P, R181C and E180R, are tumorigenic in mice with a (partial) LOF phenotype 62–64 .”
p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints
Lukin, D. J., Carvajal, L. A., Liu, W.-J., Resnick‐Silverman, L., & Manfredi, J. J. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0177 · Cited by 92
“The relevance of the growth arrest response to tumor suppression has recently been highlighted by studies using a tumor-derived mutant p53 defective for apoptosis but competent for growth arrest (3).”
Probing p53 biological functions through the use of genetically engineered mouse models
Attardi, L. D., & Donehower, L. A. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.022 · Cited by 98
Pant, V., Xiong, S., Jackson, J. G., Post, S. M., Abbas, H. A., Quintás-Cardama, A., Hamir, A. N., & Lozano, G. (2013) · Genes & Development · doi:10.1101/gad.227249.113 · Cited by 84
“Previously, our laboratory had shown that p53 mice express a mutant form of p53 (p53R172P) that activates only cell cycle arrest (partially) but not apoptotic programs (Liu et al. 2004).”
BackgroundSelf-citationSantiago, A., Li, D., Zhao, L., Godsey, A. C., & Liao, D. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-10-0771 · Cited by 98
“In contrast to the R175H mutant, the R175P mutant likely maintains the structural integrity of p53, as it remains active in transactivation (Liu et al., 2004).”
BackgroundTargeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 106
“This suggested that alternative mechanisms are involved in p53 associated tumorigenesis (57, 58).”
BackgroundRegulation of Metabolic Activity by p53
Flöter, J., Kaymak, I., & Schulze, A. (2017) · Metabolites · doi:10.3390/metabo7020021 · Cited by 81
“to DNA damage and prevents apoptosis or senescence in cancer cells [27-29].”
BackgroundImportance of DNA damage checkpoints in the pathogenesis of human cancers
Poehlmann, A., & Roessner, A. (2010) · Pathology - Research and Practice · doi:10.1016/j.prp.2010.06.006 · Cited by 101
Therapeutic targeting of p53 by small molecules
Selivanova, G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.006 · Cited by 93
ATM and p21 Cooperate to Suppress Aneuploidy and Subsequent Tumor Development
Shen, K. C., Heng, H. H., Wang, Y., Lu, S., Liu, G., Deng, C., Brooks, S. C., & Wang, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1471 · Cited by 87
Self-citationp53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo
Timofeev, O., Schlereth, K., Wanzel, M., Braun, A., Nieswandt, B., Pagenstecher, A., Rosenwald, A., Elsässer, H.-P., & Stiewe, T. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.008 · Cited by 76
“Importantly, although the p53 mutant is apoptosis deficient, it was shown to suppress spontaneous tumorigenesis and maintain genomic stability due to its intact cell-cycle arrest and senescence functions (Cosme-Blanco et al., 2007; Liu et al., 2004; Van Nguyen et al., 2007).”
BackgroundInfluentialGuilt by association? p53 and the development of aneuploidy in cancer
Duensing, A. U., & Duensing, S. M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.157 · Cited by 82
What have animal models taught us about the p53 pathway?
Lozano, G., & Zambetti, G. P. (2005) · The Journal of Pathology · doi:10.1002/path.1704 · Cited by 76
“A new p53 mutant mouse, however, was generated to distinguish the importance of apoptosis versus cell-cycle arrest functions of p53 in spontaneous tumourigenesis in vivo [112].”
BackgroundMethodSelf-citationDefining a role for sphingosine kinase 1 in p53-dependent tumors
Heffernan-Stroud, L. A., Helke, K. L., Jenkins, R. W., Costa, A.-M. D., Hannun, Y. A., & Obeid, L. M. (2011) · Oncogene · doi:10.1038/onc.2011.302 · Cited by 81
“This conclusion is further supported by an elegant study in which an apoptosisdeficient p53 mutant mouse that retained p53-dependent cell cycle arrest and senescence was still protected from thymic lymphoma development, thus ruling out a role for apoptosis in the tumor-suppressive action of p53 (Liu et al., 2004).”
Koso, H., Takeda, H., Yew, C. C. K., Ward, J. M., Nariai, N., Ueno, K., Nagasaki, M., Watanabe, S., Rust, A. G., Adams, D. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215899109 · Cited by 74
“S1A), indicating that the p53 mutation does not induce pronounced aneuploidy in immortalized cells, consistent with the findings of a previous study (18).”
ResultDNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model
Van Nguyen, T., Puebla-Osorio, N., Pang, H., Dujka, M. E., & Zhu, C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062453 · Cited by 72
“Previous studies have indicated that p53R175P was able to activate p21 in irradiated cells, but at a reduced rate (10, 37, 38).”
BackgroundInfluentialTP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Soussi, T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00005-0 · Cited by 86
Attardi, L. D. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.04.019 · Cited by 88
p21WAF1/CIP1 and cancer: A shifting paradigm?
Gartel, A. L. (2009) · BioFactors · doi:10.1002/biof.26 · Cited by 71
“Previously, it has been shown that knock-in mice with p53R172P mutant (instead of p53) have prolonged survival compared to p53-null mice [21].”
BackgroundThe p53 mutation “gradient effect” and its clinical implications
Zambetti, G. P. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21217 · Cited by 71
“Genetically modifiedmice carrying the equivalent R175P mutation (R172P) survived significantly longer than the p53 / and R172H mice and succumbed to lymphoma and sarcomas between 7 and 14 months (Liu et al., 2004).”
BackgroundThe Regulation of Cellular Functions by the p53 Protein: Cellular Senescence
Tonnessen-Murray, C. A., Lozano, G., & Jackson, J. G. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026112 · Cited by 70
“This hypomorphic p53 protein still suppresses spontaneous tumor formation by a Cdkn1a-dependent mechanism (Liu et al. 2004; Barboza et al. 2006) and can also suppress Mycdriven lymphoma (Post et al.”
BackgroundSelf-citationp53: a heavily dictated dictator of life and death
Lü, X. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.008 · Cited by 80
The Ataxia Telangiectasia–Mutated Target Site Ser18 Is Required for p53-Mediated Tumor Suppression
Armata, H. L., Garlick, D. S., & Sluss, H. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1610 · Cited by 68
“A role for cell cycle arrest in p53 tumor suppression is supported by the absence of early tumors in mice with a p53 mutation at R172 (25).”
BackgroundChk2 Suppresses the Oncogenic Potential of DNA Replication-Associated DNA Damage
Stracker, T. H., Couto, S. S., Cordon‐Cardo, C., Matos, T., & Petrini, J. H. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.028 · Cited by 69
“The significance of the G1/S checkpoint in this regard has been previously suggested from the analysis of mice expressing the p53515C/515C (R172P) allele (Liu et al., 2004).”
BackgroundChromosome instability in neoplasia: chaotic roots to continuous growth
Gagos, S., & Irminger‐Finger, I. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.01.003 · Cited by 78
Wijnhoven, S. W. P., Zwart, E., Speksnijder, E. N., Beems, R. B., Olive, K. P., Tuveson, D. A., Jonkers, J., Schaap, M. M., van den Berg, J., Jacks, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1650 · Cited by 64
Tavana, O., Benjamin, C. L., Puebla-Osorio, N., Sang, M., Ullrich, S. E., Ananthaswamy, H., & Zhu, C. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12688 · Cited by 63
Crippling p53 activities via knock-in mutations in mouse models
Iwakuma, T., & Lozano, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210278 · Cited by 84
“To decipher the functional importance of cell-cycle arrest in absence of p53dependent apoptosis on spontaneous tumorigenesis, mice carrying this mutation (172 in the mouse) were Oncogene generated (p53R172P) (Liu et al., 2004).”
BackgroundSelf-citationGeneration of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells
Honma, M. (2005) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20113 · Cited by 67
“Even though aneuploidy associated with centrosome amplification is a characteristic of typical p53-deficient cells, some mutant p53 cell lines do not show an enhancement of aneuploid cells via centrosome amplification [Liu et al., 2004].”
The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development
Liu, G., Terzian, T., Xiong, S., Van Pelt, C., Audiffred, A., Box, N., & Lozano, G. (2007) · The Journal of Pathology · doi:10.1002/path.2238 · Cited by 61
“Mice p53 515C /515C mice were crossed with Mdm2 +/− mice [10,19].”
BackgroundMethodInfluentialSelf-citationThe p53–PUMA axis suppresses iPSC generation
Li, Y., Feng, H., Gu, H., Lewis, D. W., Yuan, Y., Zhang, L., Yu, H. M., Zhang, P., Cheng, H., Miao, W., et al. (2013) · Nature Communications · doi:10.1038/ncomms3174 · Cited by 66
Uo, T., Kinoshita, Y., & Morrison, R. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3222-05.2007 · Cited by 67
Illuminating p53 function in cancer with genetically engineered mouse models
Garcia, P. B., & Attardi, L. D. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2013.12.014 · Cited by 59
Lynch, C. J., & Milner, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209387 · Cited by 66
Tavana, O., Puebla-Osorio, N., Sang, M., & Zhu, C. (2010) · Diabetes · doi:10.2337/db09-0792 · Cited by 58
“Interestingly, a hypomorphic mutant p53, p53 (referred to as p53), which is defective in apoptosis but not in cell cycle arrest (11), not only rescues embryonic lethality but also entirely eliminates lymphomagenesis in the Lig4 / (12).”
Backgroundp53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis
Post, S. M., Quintás-Cardama, A., Terzian, T., Smith, C., Eischen, C. M., & Lozano, G. (2010) · Oncogene · doi:10.1038/onc.2009.423 · Cited by 58
“Genotyping and lymphoma analysis Tails from Em-myc::p53þ /þ , Em-myc::p53515C/515C, Em-myc:: p53515C/þ or Em-myc::p53þ /– mice were genotyped using primers previously described (Jacks et al., 1994b; Eischen et al., 1999; Liu et al., 2004).”
BackgroundMethodInfluentialSelf-citationRisk genes in head and neck cancer: A systematic review and meta-analysis of last 5years
Brunotto, M. N., Zárate, A. M., Bono, A., Barra, J. L., & Berra, S. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.12.007 · Cited by 67
“It is known that the p53 suppressor tumor gene has a key role in stress cellular response, to preserve genome stability, and it is universally recognized as a human cancer marker when it is mutated [2,31–34].”
BackgroundTranscriptional functionality of germ line p53 mutants influences cancer phenotype
Monti, P., Ciribilli, Y., Jordan, J., Menichini, P., Umbach, D. M., Resnick, M. A., Luzzatto, L., Inga, A., & Fronza, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2545 · Cited by 58
The Bcl-2 protein family and its role in the development of neoplastic disease
Heiser, D., Labi, V., Erlacher, M., & Villunger, A. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.04.011 · Cited by 64
Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa117 · Cited by 53
Cell cycle- and DNA repair pathway-specific effects of apoptosis on tumor suppression
Foster, S. S., De, S., Johnson, L. K., Petrini, J. H. J., & Stracker, T. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120476109 · Cited by 59
“We compared the apoptotic and cell-cycle checkpoint responses of Nbs1 Chk2 double mutants with those seen with the p53 mutation, which impairs apoptosis but retains the cell-cycle functions (12).”
BackgroundResultInfluentialp53 suppresses carcinoma progression by inhibiting mTOR pathway activation
Akeno, N., Miller, A. L., Ma, X., & Wikenheiser‐Brokamp, K. A. (2014) · Oncogene · doi:10.1038/onc.2013.589 · Cited by 65
Splicing DNA-damage responses to tumour cell death
Crighton, D., & Ryan, K. M. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.09.001 · Cited by 63
The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death
Chari, N. S., Pinaire, N. L., Thorpe, L., Medeiros, L. J., Routbort, M. J., & McDonnell, T. J. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0327-9 · Cited by 65
“This mutation, although rare, is able to induce cell cycle arrest by the upregulation of p21 but fails to transactivate the bax promoter or induce apoptosis [39].”
Backgroundp53 partial loss-of-function mutations sensitize to chemotherapy
Klimovich, B., Merle, N., Neumann, M., Elmshäuser, S., Nist, A., Mernberger, M., Kazdal, D., Stenzinger, A., Timofeev, O., & Stiewe, T. (2022) · Oncogene · doi:10.1038/s41388-021-02141-5 · Cited by 53
“Of note, mice carrying a hypomorphic p53 allele or the murine partial-LOF variant R172P (corresponding to human R175P) succumb prematurely to cancer proving that partial-LOF mutations are pathogenic despite their residual tumor suppressive activity [15, 16].”
BackgroundInsights from mouse models into human retinoblastoma
MacPherson, D. P. (2008) · Cell Division · doi:10.1186/1747-1028-3-9 · Cited by 51
“p53 independent of apoptosis are critical for tumor suppressor ability [57].”
BackgroundThe TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
“Mice homozygous for the p.R172P mutation (equivalent to the human p.R175P alteration) exhibit defects in TP53 -dependent apoptosis but retain a partial cell cycle checkpoint function [44].”
Acin, S., Li, Z., Mejia, O., Roop, D. R., El‐Naggar, A. K., & Caulin, C. (2011) · The Journal of Pathology · doi:10.1002/path.2971 · Cited by 49
Self-citationNew approaches for modelling cancer mechanisms in the mouse
Maddison, K., & Clarke, A. R. (2005) · The Journal of Pathology · doi:10.1002/path.1698 · Cited by 61
Saha, T., Ghosh, S., Vassilev, A. P., & Depamphilis, M. (2006) · Journal of Cell Science · doi:10.1242/jcs.02851 · Cited by 48
“Thus, it is surprising that Tp53-dependent apoptosis is not required for suppression of the early onset of spontaneous tumors during mouse development; only the ability of Tp53 to induce cell-cycle arrest and retain chromosome stability is required (Liu et al., 2004).”
BackgroundThe Mre11 Complex Suppresses Oncogene-Driven Breast Tumorigenesis and Metastasis
Gupta, G. P., Vanness, K., Barlas, A., Manova-Todorova, K. O., Wen, Y. H., & Petrini, J. H. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.09.001 · Cited by 48
“The genotypes analyzed were Mre11, Nbs1, Chk2 / , Nbs1 Chk2 / , p53, p53 / , and 53BP1 / , each of which exhibits defects in DNA-damage-induced cell-cycle checkpoint activation, apoptosis, and/or DNA repair (Figures S1A and S1B available online; Liu et al., 2004; Shibata et al., 2010; Stracker et al., 2007, 2008; Stra…”
BackgroundMethodInfluentialInduction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53
Quinn, B. A., Brake, T., Xiang, H., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008404 · Cited by 49
“Mice harboring mutant p53 allele(s) were genotyped as previously described [51] using primers PL5-59-ACCTGTAGCTCCAGCACTGG-39, PL6-59-ACAAGCCGAGTAACGATCAGG-39 and NeoR-59-CCATTTGTCACGTCCTGCACG-39.”
MethodDekanty, A., Barrio, L., & Milán, M. (2014) · Oncogene · doi:10.1038/onc.2014.42 · Cited by 47
Avivi, A., Ashur‐Fabian, O., Joel, A., Trakhtenbrot, L., Adamsky, K., Goldstein, I., Amariglio, N., Rechavi, G., & Nevo, E. (2006) · Oncogene · doi:10.1038/sj.onc.1210045 · Cited by 48
Transcription factor p53 in degenerating spinal cords
Eve, D. J., Dennis, J. S., & Citron, B. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.088 · Cited by 51
Malek, R. A., Matta, J. L., Taylor, N. E., Perry, M. E., & Mendrysa, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017884 · Cited by 53
“Furthermore, the early death of these mice precluded an assessment of the consequences of MDM2 loss in tumorigenesis or behavior [36,37].”
BackgroundIroning out how p53 regulates ferroptosis
Murphy, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615159113 · Cited by 51
Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
Boyarskikh, U. A., Gulyaeva, L. F., Avdalyan, A. M., Андреевич, К. А., Khrapov, E. A., Lazareva, D. G., Кушлинский, Н. Е., Melkonyan, A., Arakelyan, A., & Филипенко, М. Л. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01103 · Cited by 47
“In this case, the mutant retains some pro-survival functions and selectively loses tumor-suppressive activity of p53 wild-type, as shown for the apoptosis-deficient R175P mutant p53 (4).”
BackgroundInfluentialAtm Deficiency Affects Both Apoptosis and Proliferation to Augment Myc-Induced Lymphomagenesis
Maclean, K. H., Kastan, M. B., & Cleveland, J. L. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0058 · Cited by 42
“dual tumor suppressor mechanism (apoptosis and growth arrest) suggested here for ATM is similar to the scenario for p53, where both its proapoptotic (8, 50) and antiproliferative (51) effects have been shown to contribute to its tumor-suppressive properties.”
Backgroundp53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors
Slatter, T. L., Ganesan, P. L., Holzhauer, C., Mehta, R., Rubio‐Terres, C., Williams, G., Wilson, M., Royds, J. A., Baird, M. A., & Braithwaite, A. W. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.136 · Cited by 46
Molecular profile of atypical hyperplasia of the breast
Danforth, D. N. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4488-x · Cited by 41
Ceballos, E., Muñoz-Alonso, M. J., Berwanger, B., Acosta, J. C., Hernández, R., Krause, M., Hartmann, O., Eilers, M., & León, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208652 · Cited by 55
An LTR retrotransposon‐derived lncRNA interacts with RNF169 to promote homologous recombination
Deng, B., Xu, W., Wang, Z., Liu, C., Lin, P., Li, B., Huang, Q., Yang, J., Zhou, H., & Qu, L. (2019) · The EMBO Reports · doi:10.15252/embr.201847650 · Cited by 40
“As reported, cells harboring p53 hot spot mutants often have high HR activity to overcome serious DNA damage [23,63], and exacerbated HR activity contributes to genome instability and tumorigenesis [21–23].”
Merino, D. M., & Malkin, D. M. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_1 · Cited by 47
Restoring p53 in cancer: the promises and the challenges
Lozano, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz063 · Cited by 42
“and senescent functions of p53 are also tumor suppressive (Liu et al., 2004; Chen et al., 2005), they do not”
BackgroundSelf-citationSynthesis of 5-deazaflavin derivatives and their activation of p53 in cells
Wilson, J. M., Henderson, G., Black, F., Sutherland, A. J., Ludwig, R. L., Vousden, K. H., & Robins, D. J. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.011 · Cited by 43
Chromosome instability and deregulated proliferation: an unavoidable duo
Coschi, C. H., & Dick, F. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0910-4 · Cited by 42
Screening of Hub Genes and Pathways in Colorectal Cancer with Microarray Technology
Wang, Y., & Zheng, T. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-013-9739-5 · Cited by 39
“It also contributes to chromosome stability [32] as well as mitochondrial genetic stability [33], which are critical for suppression of tumorigenesis [34, 35].”
Backgroundp53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen
Valente, L. J., Tarangelo, A., Li, A. M., Naciri, M., Raj, N., Boutelle, A. M., Li, Y., Mello, S. S., Bieging-Rolett, K. T., DeBerardinis, R. J., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201908212 · Cited by 38
“p53 is thought to preserve genomic integrity by inducing G1 arrest when cells have sustained DNA damage or have undergone aberrant mitosis with consequent ploidy anomalies, known as the tetraploidy checkpoint (Fujiwara et al., 2005; Ganem et al., 2014; Lanni and Jacks, 1998; Liu et al., 2004).”
BackgroundMyc, Cdk2 and cellular senescence: Old players, new game
Campaner, S., Doni, M., Verrecchia, A., Fagà, G., Bianchi, L., & Amati, B. B. (2010) · Cell Cycle · doi:10.4161/cc.9.18.13049 · Cited by 44
Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis
Roszkowska, K. A., Giziński, S., Sady, M., Gajewski, Z., & Olszewski, M. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041334 · Cited by 39
“Interestingly, no change in metastasis or survival was found in Trp53+/R172P mice [20].”
BackgroundTumor Suppression by p53: Fall of the Triumvirate?
Hock, A. K., & Vousden, K. H. (2012) · Cell · doi:10.1016/j.cell.2012.05.024 · Cited by 41
“Other p53 mutants that are defective in apoptosis or cell-cycle arrest have been shown to retain tumor suppressor activity (Brady et al., 2011; Liu et al., 2004), although in these cases at least one of the ‘‘big three’’ responses was retained.”
Backgroundp53: Its Mutations and Their Impact on Transcription
Vaughan, C. A., Pearsall, I., Yeudall, W. A., Deb, S. P., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_4 · Cited by 40
“[ 91 , 92 ] demonstrated an increased metastatic potential in mice inheriting p53-R172H (homologous to human p53-R175H).”
BackgroundWang, Y., Wang, X., Flores, E. R., Yu, J., & Chang, S. S. (2016) · Aging Cell · doi:10.1111/acel.12476 · Cited by 41
Self-citationJoliot, V., Cormier, F., Medyouf, H., Alcalde, H., & Ghysdael, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209480 · Cited by 37
“…relative importance of cell cycle regulation, maintenance of genomic stability and apoptosis control in the tumor suppressive function of p53 appears to be distinct in the B- and T-cell lineages, with apoptosis playing a prevalent role in the B-cell lineage (Schmitt et al., 2002; Liu et al., 2004).”
BackgroundIdentifying and Targeting the Cause of Cancer is Needed to Cure Cancer
Adjiri, A. (2016) · Oncology and Therapy · doi:10.1007/s40487-015-0015-6 · Cited by 45
“p53 is the quintessential guardian of the genome stability [41] and mutations in this transcription factor are among the most common genetic alterations in human cancer; being mutated in A.”
BackgroundWest, A. N., Ribeiro, R. C., Jenkins, J., Galindo, C. R., de Figueiredo, B. C., Kriwacki, R. W., & Zambetti, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4580 · Cited by 34
“Although a number of knock-in mutant p53 mouse models have been recently generated to test the effects of different amino acid substitutions in a selected site (26, 29, 30), the identification of the R175L mutation in a family with a child who developed an adrenal cortical tumor offers a unique opportunity to study th…”
Backgroundp53 and regulation of bioactive sphingolipids
Heffernan-Stroud, L. A., & Obeid, L. M. (2010) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2010.10.003 · Cited by 37
“…with mutations in p53 that abrogate its apoptotic signaling but maintain its induction of p21 and senescence, protect chromosome stability and delay tumor onset compared to full knockout of p53, highlighting the importance of cell cycle arrest in p53-induced tumor suppression (Liu et al., 2004).”
The ups and downs of p53 regulation in hematopoietic stem cells
Abbas, H. A., Pant, V., & Lozano, G. (2011) · Cell Cycle · doi:10.4161/cc.10.19.17721 · Cited by 33
Self-citationResidual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
Timofeev, O. N., Klimovich, B., Schneikert, J., Wanzel, M., Pavlakis, E., Noll, J., Mutlu, S., Elmshäuser, S., Nist, A., Mernberger, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019102096 · Cited by 33
“In contrast, the R175P mutant, which also lacks the ability to transactivate pro-apoptotic target genes but belongs to the class of structural mutations (Rowan et al , 1996; Liu et al , 2004), failed to trigger apoptosis in the presence of doxorubicin and Nutlin (Fig 5H).”
BRCA1/P53: Two strengths in cancer chemoprevention
Raimundo, L., Ramos, H., Loureiro, J. B., Calheiros, J., & Saraiva, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188339 · Cited by 32
Dual roles of telomere dysfunction in initiation and suppression of tumorigenesis
Cosme‐Blanco, W., & Chang, S. S. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.011 · Cited by 34
“Cells harboring this mutation (p53P/P) are incapable of activating apoptosis (Liu et al, 2004), but the senescence pathway is intact as induction of telomere damage through overexpression of TRF2-DN in these cells led to dramatic reduction of cellular proliferation and the appearance of senescent…”
BackgroundSelf-citationTargeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas
Benítez, J. A., Arregui, L., Vergara, P., & Segovia, J. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701076 · Cited by 30
Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice
van Kranen, H. J., Westerman, A., Berg, R. J. W., Kram, N. R., van Kreijl, C. F., Wester, P. W., & de Gruijl, F. R. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.07.018 · Cited by 33
Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice
Donehower, L. A. (2014) · Human Mutation · doi:10.1002/humu.22507 · Cited by 29
“The first two reported germline missense mutations were Trp53 R172H and R172P, both generated by the Lozano laboratory [Liu et al., 2000; Lang et al., 2004; Liu et al., 2004].”
BackgroundCD1d-restricted peripheral T cell lymphoma in mice and humans
Bachy, E., Urb, M., Chandra, S., Robinot, R., Bricard, G., de Bernard, S., Traverse‐Glehen, A., Gazzo, S., Blond, O., Khurana, A., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20150794 · Cited by 32
“In sharp contrast to the well‐ documented aneuploidy observed in TLs (Liu et al., 2004) and to the two TLs that served as positive controls in our study, no clonal translocation or chromosomes number alter‐ ations were observed in PTCLs (Fig.”
ResultLoss of Nuclear Factor-κB Is Tumor Promoting but Does Not Substitute for Loss of p53
Ryan, K. M., O’Prey, J., & Vousden, K. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1474 · Cited by 31
“However, because this effect of TNF- does not manifest itself in E1a/Ras tumors, and in light of recent results showing that a nonapoptotic p53 mutant retains some tumor suppressor activity (18), it also seems possible that the failure of the E1A p65-null cells to form tumors in mice reflects the retention of addition…”
BackgroundEssential roles for Pot1b in HSC self-renewal and survival
Wang, Y., Shen, M., & Chang, S. S. (2011) · Blood · doi:10.1182/blood-2011-06-361527 · Cited by 31
Self-citationLi, X., Wilson, A. F., Du, W., & Pang, Q. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.006 · Cited by 33
“To test this hypothesis, we crossed our Fanca / mice to a mutant p53 mouse strain harboring a separation-of-function mutation in p53, p53515C, in which its apoptotic function is abolished but its cell-cycle checkpoint activities remain intact (Liu et al., 2004).”
BackgroundMethodInfluentialKeePin’ the p53 Family in Good Shape
Mantovani, F., Gostissa, M., Collavin, L., & Sal, G. D. (2004) · Cell Cycle · doi:10.4161/cc.3.7.999 · Cited by 32
Avivi, A., Ashur‐Fabian, O., Amariglio, N., Nevo, E., & Rechavi, G. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1534 · Cited by 31
p53: Multiple Facets of a Rubik's Cube
Zhang, Y., & Lozano, G. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121926 · Cited by 28
“A p53 missense mutant, p53R175P (R172P in the mouse), observed in a few human cancers that eliminates the apoptotic function of p53 but retains a partial cell cycle arrest phenotype showed delayed tumor development, implicating cell cycle arrest as a tumor suppressive mechanism (Liu et al. 2004).”
BackgroundSelf-citationPan, M., & Blattner, C. (2021) · Cancers · doi:10.3390/cancers13040745 · Cited by 29
Models and mechanisms in malignant melanoma
Benjamin, C. L., Melnikova, V. O., & Ananthaswamy, H. N. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20353 · Cited by 33
p53 must be competent for transcriptional regulation to suppress tumor formation
Nistér, M., Tang, M., Zhang, X., Yin, C., Beeche, M., Hu, X., Enblad, G., Dyke, T. V., & Wahl, G. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208354 · Cited by 28
Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review
Lone, W., Alkhiniji, A., Umakanthan, J. M., & Iqbal, J. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0460-z · Cited by 26
Tumor Susceptibility and Apoptosis Defect in a Mouse Strain Expressing a Human p53 Transgene
Dudgeon, C., Kek, C., Demidov, O. N., Saito, S., Fernandes, K., Diot, A., Bourdon, J., Lane, D. P., Appella, E., Fornace, A. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2063 · Cited by 28
“suggested that the ability of p53 to retain chromosomal stability, but not apoptosis activation, could be critical for suppression of early-onset tumorigenesis (39).”
BackgroundOhno, K., Ishihata, K., Tanaka-Azuma, Y., & Yamada, T. (2008) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.07.002 · Cited by 31
Metadata
- Authors
- Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Lozano, Guillermina
- Venue
- Nature Genetics
- Published
- 2003-12-21
- Volume
- 36
- Issue
- 1
- Pages
- 63-68
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1970378023
- Cited by
- 325
- References
- 30
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 12 · 2019: 15 · 2018: 9 · 2017: 11 · 2016: 16 · 2015: 5 · 2014: 15 · 2013: 18 · 2012: 19
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kadoorie Charitable Foundation
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- p53, chromosome stability, apoptosis, tumor suppression, spontaneous tumor development, thymic lymphoma, sarcoma, aneuploidy, cell cycle arrest, senescence, diploidy
- MeSH terms
- Animals, Cell Cycle, Lymphoma, Mice, Mutant Strains, Ploidies, Genes, p53, Apoptosis, Chromosomal Instability, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.